,i #aafth ,,congress #b;d ,session ,h4 ,r4 #ijbg ,,in ,,the ,,house ,,of ,,representatives ,december #ah1 #bjbj,mr4 ,beyer introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce1 and in addition to the ,committee on ,ways and ,means1 for a period to be subsequently determined by the ,speaker1 in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned ,a ,,bill ,to authorize the ,patient-,centered ,outcomes ,research ,institute to fund research of the symptoms of ,,covid-#ai1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,,covid-#ai ,long ,haulers ,act4 #b4 ,authorization to fund research of the long-term symptoms of ,,covid-#ai by the ,patient-,centered ,outcomes ,research ,institute 7a7 ,in general ,the ,patient-,centered ,outcomes ,research ,institute under section #aaha7;b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;e7b77 shall fund research described in subsection 7b74 7b7 ,research described ,for purposes of subsection 7a71 research described in this subsection shall include-- 7#a7 prior to creating a patient registry described in paragraph 7#b71 survey existing patient registries that include individuals experiencing post-acute sequelae of ,,covid-#ai2 7#b7 creating a patient registry for those with ,,covid-#ai with information that-- 7,a7 contains the-- 7i7 symptoms that arise while an individual is actively infected with ,,covid-#ai and that resolve while such individual is actively infected2 7ii7 symptoms that arise while an individual is actively infected with ,,covid-#ai and that extend after the infection has resolved2 7iii7 symptoms that arise after an individual is actively infected with ,,covid-#ai and that endure and that the clinician of such individual has reason to suspect were related to the ,,covid-#ai diagnosis2 7iv7 symptoms that arise in an individual that may be related to ,,covid-#ai but a diagnosis of ,,covid-#ai was not obtained and cannot be identified due to a lack of antibodies2 7v7 treatments of individuals after primary diagnosis to ,,covid-#ai and the effectiveness of such treatments disaggregated by age1 gender1 and race or ethnicity2 and 7vi7 any other relevant questions or issues related to individuals who experience a diagnosis of1 treatment for1 and management of care with ,,covid-#ai2 7,b7 synthesizes information relating to individuals experiencing post-acute sequelae of ,,covid-#ai identified from the survey described in paragraph 7#a7 and information under the patient registry described in paragraph 7#b72 and 7#c7 outreach and inclusion 7as appropriate7 individuals from communities with traditional health disparities and inequities4 7c7 ,report ,not later than #a year after the establishment of the synthesized patient registry described in subsection 7a77#b71 and annually thereafter1 the ,patient-,centered ,outcomes ,research ,institute shall submit data1 findings1 and information with respect to the status of the patient registry 7including progress1 barriers1 and issues7 to ,congress and the ,president4 7d7 ,authorization of appropriations ,there is hereby authorized #cj1jjj1jjj for fiscal year #bjba to carry out this section1 which shall remain available until expended4 #c4 ,authorization of appropriations for research with respect to individuals experiencing post-acute sequelae of ,,covid-#ai by the ,,nih 7a7 ,in general ,the ,director of the ,national ,institutes of ,health conduct research with respect to individuals experiencing post-acute sequelae of ,,covid-#ai4 7b7 ,authorization of appropriations ,there is hereby authorized #ajj1jjj1jjj for fiscal year #bjba to carry out this section1 which shall remain available until expended4